Bioatla Inc   (BCAB)
Other Ticker:  
Price: $2.7000 $0.03 1.124%
Day's High: $2.8084 Week Perf: 8.87 %
Day's Low: $ 2.58 30 Day Perf: 35.34 %
Volume (M): 317 52 Wk High: $ 4.07
Volume (M$): $ 856 52 Wk Avg: $2.54
Open: $2.68 52 Wk Low: $1.24

 Market Capitalization (Millions $) 129
 Shares Outstanding (Millions) 48
 Employees -
 Revenues (TTM) (Millions $) -
 Net Income (TTM) (Millions $) -124
 Cash Flow (TTM) (Millions $) -37
 Capital Exp. (TTM) (Millions $) 0

Bioatla Inc
Bioatla Inc is a biotechnology company that focuses on developing antibody-based therapeutics for the treatment of cancer and other diseases. The company utilizes its proprietary Bioaccelerator' platform, which enables the discovery and optimization of therapeutic antibodies with enhanced selectivity and potency. Bioatla's approach combines bioinformatics, protein engineering, and cell biology to create targeted therapies that have the potential to improve patient outcomes. The company's pipeline includes multiple novel antibody candidates in various stages of development, addressing different cancer types and other indications. Bioatla Inc is dedicated to advancing precision medicine through its innovative antibody-based approach to therapy.

   Company Address: 11085 Torreyana Road San Diego 92121 CA
   Company Phone Number: 558-0708   Stock Exchange / Ticker: NASDAQ BCAB
   BCAB is expected to report next financial results on March 22, 2024.


Stock Performances by Major Competitors

5 Days Decrease / Increase
• View Complete Report

Clinical Study

BioAtla Hosts Virtual R&D Day to Unveil Promising Phase 1 Data for BA3071 CAB-CTLA-4 in Multiple Solid Tumor Types

Published Wed, Dec 6 2023 1:00 PM UTC

BioAtla, a distinguished global clinical-stage biotechnology company specializing in the development of Conditionally Active Biologic (CAB) antibody therapeutics for the treatment of solid tumors, recently announced plans to host a virtual R&D Day on December 13, 2023. During this event, the company aims to review and discuss the groundbreaking Phase 1 data for the...

Clinical Study

BioAtla's BA3011: Unveiling a Ray of Hope for Heavily Pre-Treated NSCLC Patients

Published Tue, Dec 5 2023 1:00 PM UTC

In a recent press release, BioAtla, a leading clinical-stage biopharmaceutical company, presented data from their Phase 2 clinical trial at the IASLC 2023 North America Conference on Lung Cancer. The study, referred to as the BA3011 clinical trial, focused on non-small cell lung cancer (NSCLC) patients with non-squamous histology who had previously undergone extens...

Bioatla Inc

Bioatla Inc's Financial Quarter Plunges: Operating Shortfall and Zero Revenue Spark Investor Worries

The third quarter of 2023 has proven to be a challenging period for Bioatla Inc, a global clinical-stage biotechnology company focused on the development of Conditionally Active Biologic (CAB) antibody therapeutics for the treatment of solid tumors. The sector veterans examining the company's performance have noted an alarming operating shortfall of $-35.02 million during this time frame. What is even more concerning is the fact that Bioatla Inc has not reported any revenue for the July to September period, leading investors to question the company's viability.
The absence of revenue is a significant red flag for any company, especially one operating in the biotechnology and pharmaceuticals sector. Shareholders of Bioatla Inc were eagerly anticipating a new business strategy to be announced during this quarter, but thus far, the company has failed to provide any updates in this regard. This lack of transparency and communication only adds to the growing concerns amongst investors.

Bioatla Inc

Bioatla Inc Weathers Storm, Posts 2023 Q2 Loss Amidst Fierce Pharma Industry Competition

In the world of Biotechnology & Pharmaceuticals, Bioatla Inc is one of the lesser-known companies that has recently released its financial results. The company reported an operating loss of $-37.201 million for the second quarter of 2023, which is a significant increase from the operating loss of $-29.055 million in the same quarter of the previous year.
However, what has caught the attention of investors is the possibility of Bioatla Inc starting to generate positive revenue. It is not uncommon for companies in this industry to experience ups and downs as they strive to develop a successful business model. The period from April to June 2023 seemed to be one of these challenging phases for Bioatla Inc, as the net loss widened to $-35.752 million.



About us


CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2024 CSIMarket, Inc. All rights reserved. This site uses cookies to make your browsing experince better. By using this site, you agree to the Terms of Service and Privacy Policy - UPDATED (Read about our Privacy Policy)

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com